Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. We can tell because the short people scurried off to their respective destinations faster than usual this morning. But busy is a good thing, or so they say. For those of you who may need some convincing, perhaps you would like to join us for a cup or three of stimulation. Our choice today is almond toffee, should you track this sort of thing. Meanwhile, here are a few tidbits to get you started. Once again, we wish you the best as you attempt to conquer the world. And as always, please do keep in touch. …

Lord Jim O’Neill, a former chief economist at Goldman Sachs who advised the U.K. government on antibiotic resistance, is shocked by drug makers failing to tackle drug-resistant infections and suggests the solution may be to “just take it away from them and take it over,” the BBC says. There has not been a new class of antibiotic since the 1980s. In a 2016 report, he proposed giving companies around $1 billion for each novel antibiotic developed. “There’s endless talk but there’s no progress in waking up the pharmaceutical industry to want to do this,” he says.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.